公开(公告)号：US20160046910A1

公开(公告)日：2016-02-18

申请号：US14926761

申请日：2015-10-29

Applicant: OSPEDALE SAN RAFFAELE S.R.L. ,  Fondazione Telethon

Inventor： Silvia Adriana GREGORI ,  Maria Grazia RONCAROLO ,  Rosa BACCHETTA

IPC: C12N5/0783 ,  A61K35/17

CPC classification number: C12N5/0637 ,  A61K35/17 ,  A61K2035/122 ,  A61K2035/124 ,  C12N5/0636 ,  C12N5/064 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/231 ,  C12N2502/1121 ,  C12N2506/115

Abstract: The present invention relates to a tolerogenic dendritic cell population (Tr-DC) capable of generating a population of T cells having regulatory activity, method of production and uses thereof. Furthermore, soluble HLA-G promotes the differentiation of a population of T cells with regulatory activity.

Abstract translation: 本发明涉及能够产生具有调节活性的T细胞群体及其用途的耐受性树突状细胞群体（Tr-DC）。 此外，可溶性HLA-G促进具有调节活性的T细胞群体的分化。

公开(公告)号：US20250114386A1

公开(公告)日：2025-04-10

申请号：US18926669

申请日：2024-10-25

Applicant: OSPEDALE SAN RAFFAELE S.R.L. ,  FONDAZIONE CENTRO SAN RAFFAELE

Inventor： Attilio BONDANZA ,  Monica CASUCCI ,  Beatrice GRECO

IPC: A61K31/7004 ,  A61K31/145 ,  A61K31/407 ,  A61K31/437 ,  A61K31/7008 ,  A61K31/7072 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C12N5/0783

Abstract: The present invention relates to at least one glycosylation inhibitor for use in combination with CAR cell therapy. Preferably the glycosylation inhibitor improves the therapeutic potential of the CAR cell therapy. The invention also relates to pharmaceutical composition and to population or subpopulation of CAR cell that has been contacted with at least one glycosylation inhibitor.

公开(公告)号：US20250064974A1

公开(公告)日：2025-02-27

申请号：US18726752

申请日：2023-01-06

Applicant: UCL BUSINESS LTD ,  Ospedale San Raffaele S.r.l

Inventor： Gabriele LIGNANI ,  Dimitri KULLMANN ,  Stephanie SCHORGE ,  Yichen QIU ,  Francisco MOREIRA ,  Gaia COLASANTE ,  Vania BROCCOLI

IPC: A61K48/00 ,  A61K38/17 ,  A61P25/08 ,  C12N9/22 ,  C12N15/11 ,  C12N15/86

Abstract: The invention provides targeting RNA, single guide RNA, tracrRNA, crisprRNA and expression vectors for use in CRISPR activation (CRISPRa) methods for the treatment of neurological disorders and diseases, in particular epilepsy and pain. In some preferred embodiments, a combinatorial gene therapy approach is used, wherein expression of multiple endogenous human genes are increased in a subject, in order to achieve a greater rescue of seizures and/or behavioural deficits, and restore physiological brain function.

公开(公告)号：US20240408145A1

公开(公告)日：2024-12-12

申请号：US18702592

申请日：2022-10-11

Applicant: Ospedale San Raffaele S.r.l. ,  Fondazione Telethon ETS

Inventor： Rafaella Di Micco ,  Lucrezia Della Volpe ,  Anastasia Conti

IPC: A61K35/28 ,  C12N5/0789 ,  C12N15/86

Abstract: Use of one or more inhibitor(s) of senescence for increasing the survival and/or engraftment of haematopoietic cells, haematopoietic stem cells, haematopoietic progenitor cells and/or T cells in gene therapy.

公开(公告)号：US20240223884A1

公开(公告)日：2024-07-04

申请号：US18560493

申请日：2022-05-17

Applicant: OSPEDALE SAN RAFFAELE S.R.L.

Inventor： Alberto SANNA ,  Matteo ZARDIN

IPC: H04N23/611 ,  H04N23/60 ,  H04N23/63

CPC classification number: H04N23/611 ,  H04N23/63 ,  H04N23/64

Abstract: An image capturing method (100) using an image capturing apparatus (1) that comprises an imaging device (2) having an image catcher (3) for generating image data, the method (100) comprising displaying (S101), using an image reproducing device (4), images based on the image data, generating (S102) attribute data from a plurality of biological signals measured by a plurality of biological sensors (6), the attribute data being at least an information extracted by one or more biological signals through a computational processing and being indicative of attributes of a user at a time that the user is viewing the images displayed by the image reproducing device (4), generating (S103) significance data based on the attribute data, and associating the attribute data from which the significance data is generated with each displayed image, wherein the significance data are generated by comparing the attribute data with predetermined significance threshold values in order to identify a significance state for each attribute data, controlling (S104)

公开(公告)号：US20240123029A1

公开(公告)日：2024-04-18

申请号：US18275776

申请日：2022-02-08

Applicant: HUMANITAS MIRASOLE S.P.A. ,  HUMANITAS UNIVERSITY ,  OSPEDALE SAN RAFFAELE S.R.L.

Inventor： Alberto MANTOVANI ,  Cecilia GARLANDA ,  Barbara BOTTAZZI ,  Elisa VICENZI

IPC: A61K38/17 ,  A61K45/06 ,  A61P31/14 ,  C12Q1/70

CPC classification number: A61K38/178 ,  A61K45/06 ,  A61P31/14 ,  C12Q1/701 ,  C12Q2600/156 ,  C12Q2600/172

Abstract: The present invention relates to a molecule for use in the treatment and/or prevention of viral infections caused by highly pathogenic coronaviruses, including Severe Acute Respiratory syndrome Coronavirus 2 (SARS-COV-2), or variants thereof, Severe Acute Respiratory syndrome Coronavirus ((SARS)-COV) and sarbecoviruses, said molecule being a mannose binding lectin (MBL) polypeptide, or a functional fragment, derivative, mutein or variant thereof, or an homologue having a percentage of identity with MBL polypeptide of at least 50, 60, 70, 80 or 90%, preferably for use in the treatment and/or prevention of 2019 Coronavirus disease (COVID-19).

公开(公告)号：US11957713B2

公开(公告)日：2024-04-16

申请号：US16341704

申请日：2017-10-16

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION ,  OSPEDALE SAN RAFFAELE S.R.L. ,  POLITECNICO DI MILANO ,  FONDAZIONE TELETHON ETS ,  DANA-FARBER CANCER INSTITUTE, INC.

Inventor： Alessandra Biffi ,  Marco Peviani ,  Davide Moscatelli ,  Alessia Capotondo ,  Rita Milazzo ,  Umberto Capasso Palmiero

IPC: C12N5/071 ,  A61K35/12 ,  A61P25/28 ,  C12N15/86 ,  A01K67/0271 ,  A61K9/00 ,  A61K45/06

CPC classification number: A61K35/12 ,  A61P25/28 ,  C12N15/86 ,  A01K67/0271 ,  A01K2227/10 ,  A61K9/0019 ,  A61K2035/124 ,  A61K45/06 ,  C12N2740/15043

Abstract: The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.

公开(公告)号：US20230167407A1

公开(公告)日：2023-06-01

申请号：US17997377

申请日：2021-04-28

Applicant: OSPEDALE SAN RAFFAELE S.R.L.

Inventor： Barbara CAMISA ,  Monica CASUCCI ,  Silvia ARCANGELI ,  Claudia MEZZANOTTE ,  Laura FALCONE ,  Maria Chiara BONINI

IPC: C12N5/0783 ,  C12N15/86 ,  A61P35/00

CPC classification number: C12N5/0636 ,  C12N15/86 ,  A61P35/00 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2740/15043

Abstract: The present invention refers to a method to produce a T cell with advantageous properties. The invention also refers to a T cell or an engineered T cell produced by the method and its use in therapy.

公开(公告)号：US20230159985A1

公开(公告)日：2023-05-25

申请号：US17602918

申请日：2020-04-09

Applicant: Ospedale San Raffaele S.r.l. ,  Fondazione Telethon

Inventor： Eugenio Montini ,  Daniela Cesana

IPC: C12Q1/6806 ,  C12Q1/686 ,  C12Q1/6869 ,  C12N15/10

CPC classification number: C12Q1/6806 ,  C12Q1/686 ,  C12Q1/6869 ,  C12N15/1065

Abstract: A method for analysing insertion sites of an exogenous nucleotide sequence in a subject's genome, wherein the method comprises: (a) providing a sample from the subject comprising cell-free double-stranded DNA polynucleotides; (b) blunting the ends of the polynucleotides; (c) ligating an oligonucleotide to both ends of the polynucleotides; (d) amplifying polynucleotides comprising an insertion site; and (e) sequencing the product of step (d).

公开(公告)号：US11597755B2

公开(公告)日：2023-03-07

申请号：US16605561

申请日：2018-04-24

Applicant: Ospedale San Raffaele S.r.l. ,  Fondazione Centro San Raffaele

Inventor： Maria Chiara Bonini ,  Eliana Ruggiero ,  Zulma Irene Magnani ,  Luca Aldo Edoardo Vago ,  Attilio Bondanza ,  Fabio Ciceri

IPC: C07K14/725 ,  A61P35/00 ,  A61K35/17 ,  C07K14/47 ,  C12N5/0783 ,  A61K38/00

Abstract: TCR AND PEPTIDES A T-cell receptor (TCR), which binds to a Wilms tumour 1 protein (WT1) peptide when presented by a major histocompatibility complex (MHC).